Thank Jay. you,
in As detailed the is incredibly We the resubmit and Amphora you the next team getting few Amphora And for the NDA for pregnancy. The that on line. quarter the data approval know, to comprehensive of clock top of us the finish priority second around on resubmissions XXXX. working comprises the is the of keeps for track to launch schedule remain NDA Amphora our prevention to this finalize in the our package weeks.
The ID, of reality oXne diverse options a are not there's all. with no need contraceptive stark the women, that non-hormonal does the need choices, withdraw, number a for dissatisfied Research all. condoms, who is is limitations and at significant beyond of be that method are as Copper them, women a option. to size the their new method, who current rhythm There suggests control birth as fit They use frankly hormones.
moment. health women embrace for hormone free extensive proposition and control as unique our that the its We Amphora as birth market are control female used that's welcome in that confident their based will research care providers and on
their well forget Let's previous that XX% compared demonstrated that reported its an women for but only of least life in contraceptive one to Amphora who not also it or and was lot their Amphora sex sexual efficacy not methods. AMPOWER tolerated, a the increase in little better was met a trial, endpoint and at cycle used comfortably also satisfaction.
in pregnancy with that option prevents sexual for and when to is enhancer. even this, increase it keep associated in say hormones. say mind Now, that both libido women who compelling an The designed are beyond satisfaction more they as it is a not I Amphora be makes fact an
and by nearly satisfaction further XX% reporting satisfied satisfied are This the it's ASRM, see very will very contraception, at favorable a we hormonal success. last data why than satisfaction commercial believe not from being method. Amphora supported satisfaction we month easy findings consider the their or baseline collected who will with the unmet that reported that who and contraceptive study patient more These Amphora. percentage or AMPOWER overall we cannot data, the needs to is millions use double consider with presented When the and sexual women of you of of be you women suggesting
pregnancy. additional An to beyond of important long part that the Amphora for of prevention explore indications our are is term strategy
While there for are opportunities in chlamydia, its prevention infectious which due focus is the ability of the pH, reportable many on common vaginal to the most for to potential today. regulate initial the Amphora, was our U.S. disease
the chlamydia, U.S. In making need of reported of of over chlamydia million in year for and cases fact, the no with fifth XXXX, the the approved X.X last CDC very the is unmet prevention increased products month consecutive in clear. chlamydia rates were that highlighted
in and the there study enrolled use Our for duration gel were preventing at a on as favorable to vaginal as preceding time XX% reinfection trial Amphora animal to treated placebo-controlled that These month showing the XXX either to X of placebo efficacy AMPREVENCE is or of a diagnosed and or months. This gonorrhea the in-human XX time chlamydia trial who've XX risk women centers well of data interventional in in randomized been kill Amphora's XX% STI U.S. Amphora It for the and was been for women has an XX period. the conducted gonorrhea. have weeks. vitro They prevention. in chlamydia subsequent first four data, builds
were track confirm to to to X,XXX that line body right data Xb We 's to the AMPREVENCE due safety top data I'm a of Amphora later pleased move more this that into in we women. report demonstrates large month. than are on allowed Phase trial
any because be placebo don't we the on currently indicated for clinically have difference view Amphora Although win, nothing chlamydia. the would data, is and of significant yet there a prevention a between
we prevention of But first in the unmet yet Amphora data largest free, be AMPREVENCE with plan to need. in-the-moment hormone potential provide let about address U.S. chlamydia. X in term for drug will us class information another the for the the commercial need the near products We're the to clear, most is the opportunity and as The me study excited efficient confirmatory Phase Amphora establishing very
to continues can't I of wait the people they what potential we launch disruptive build trajectory is the not option. spent new that careers and the provided on confidence women's have Amphora, have in market While our to the their current and data opportunity a health, launch yet contraceptive can say entire the team, who for enthusiasm guidance for
Now U.S. the the Officer, that mindset Commercial market. and our the I'm about Chief insights going Russ to gleaned Barrans ask we've to discuss U.S. latest Russ?
